177Lu-DOTATATE efficacy and safety in functioning neuroendocrine tumors: A joint analysis of phase II prospective clinical trials

被引：0
|
作者：
Bongiovanni, A. [1 ]
Nicolini, S. [2 ]
Foca, F. [3 ]
Sansovini, M. [2 ]
Grassi, I. [2 ]
Liverani, C. [1 ]
Riva, N. [1 ]
Fausti, V. [1 ]
Mercatali, L. [1 ]
De Vita, A. [1 ]
Fabbri, L. [3 ]
Signoretti, M. [4 ]
Pacilio, C. A. [5 ]
Paganelli, G. [2 ]
Severi, S. [2 ]
Ibrahim, T. [1 ]
Tartaglia, A. [6 ]
机构：
[1] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amado, Osteoncol & Rare Tumor Ctr, Meldola, Italy
[2] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amado, Nucl Med & Radiometabol Unit, Meldola, Italy
[3] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amado, Unit Biostat & Clin Trials, Meldola, Italy
[4] Morgagni Pierantoni Hosp, Unit Gastroenterol & Digest Endoscopy, Forli, Italy
[5] Morgagni Pierantoni Hosp, Gen & Oncol Surg, Forli, Italy
[6] Morgagni Pierantoni Hosp, Unit Endocrinol, Forli, Italy
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.185
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1103P
引用
收藏
页码：S912 / S912
页数：1
相关论文
共 50 条
  • [21] NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE: Efficacy and Safety Results
    Strosberg, J.
    Wolin, E.
    Chasen, B.
    Kulke, M.
    Bushnell, D.
    Caplin, M.
    Baum, R.
    Kunz, P.
    Hobday, T.
    Hendifar, A.
    Oberg, K.
    Sierra, Lopera M.
    Kwekkeboom, D.
    Ruszniewski, P.
    Krenning, E.
    NEUROENDOCRINOLOGY, 2016, 103 : 95 - 95
  • [22] NETTER-1 phase III: efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate
    Strosberg, J.
    Wolin, E.
    Chasen, B.
    Kulke, M.
    Bushnell, D.
    Chaplin, M.
    Baum, R.
    Kunz, P.
    Hobday, T.
    Oberg, K.
    Sierra, M. Lopera
    Kwekkeboom, D.
    Ruszniewski, P.
    Krenning, E.
    Hendifar, A.
    ANNALS OF ONCOLOGY, 2016, 27 : 121 - 121
  • [23] NETTER-1 phase III: Efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177Lu-DOTATATE
    Strosberg, Jonathan R.
    Wolin, Edward M.
    Chasen, Beth
    Kulke, Matthew H.
    Bushnell, David L.
    Caplin, Martyn E.
    Baum, Richard P.
    Hobday, Timothy J.
    Hendifar, Andrew Eugene
    Oberg, Kjell E.
    Sierra, Maribel Lopera
    Kwekkeboom, Dik J.
    Ruszniewski, Philippe B.
    Krenning, Eric
    Kunz, Pamela L.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [24] Safety and Efficacy of 177Lu-DOTATATE in Neuroendocrine Tumor Patients With Extensive Bone Disease
    Alsadik, Shahad
    Gnanasegaran, Gopinath
    Chen, Luohai
    Quigley, Ann-Marie
    Mandair, Dalvinder
    Toumpanakis, Christos
    Caplin, Martyn
    Navalkissoor, Shaunak
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (08) : 667 - 672
  • [25] Therapy With 177Lu-DOTATATE: Clinical Implementation and Impact on Care of Patients With Neuroendocrine Tumors
    Kendi, A. Tuba
    Halfdanarson, Thorvardur R.
    Packard, Annie
    Dundar, Ayca
    Subramaniam, Rathan M.
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2019, 213 (02) : 309 - 317
  • [26] 177Lu-DOTATATE Treatment In Unresectable Neuroendocrine Tumors: Our Experience
    Agudelo, M.
    Bello-Arques, P.
    Olivan-Sasot, P.
    Prado-Wohlwend, S.
    Sanchez-Vano, R.
    Yepes-Agudelo, A.
    Martinez-Sanchis, B.
    Bernal-Vergara, J.
    Figueroa-Ardila, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S596 - S597
  • [27] Rapid Progression After 177Lu-DOTATATE in Patients With Neuroendocrine Tumors
    Assi, Hussein A.
    Hornbacker, Kathleen
    Shaheen, Shagufta
    Wittenberg, Theresa
    Silberman, Robyn
    Kunz, Pamela L.
    PANCREAS, 2021, 50 (06) : 890 - 894
  • [28] Comparison of 68Ga-DOTATATE and 177Lu-DOTATATE kinetics in neuroendocrine tumors
    Ilan, E.
    Lubberink, M.
    Sandstrom, M.
    Jahn, U.
    Velikyan, I.
    Andersson, C.
    Fross-Baron, K.
    Sundin, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S276 - S277
  • [29] Neoadjuvant treatment with 177Lu-DOTATATE for nonfunctional neuroendocrine tumors of the pancreas (NEOLUPANET): a multicenter phase II study
    Mintziras, Ioannis
    Bartsch, Detlef K.
    CHIRURGIE, 2025, 96 (01): : 63 - 64
  • [30] NETTER-1 Phase III in Patients With Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate: Efficacy, Safety, QoL Results, and Subgroup Analysis
    Strosberg, Jonathan
    Wolin, Edward
    Chasen, Beth
    Kulke, Matthew
    Bushnell, David
    Caplin, Martin
    Baum, Richard
    Kunz, Pamela
    Hobday, Timothy
    Hendifar, Andrew
    Oberg, Kjell
    Sierra, Maribel Lopera
    Kwekkeboom, Dik
    Ruszniewski, Philippe
    Krenning, Eric
    PANCREAS, 2017, 46 (03) : 440 - 440
12345